

# Nonmuscle invasive bladder cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/NAA18BBB78CEN.html>

Date: July 2021

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: NAA18BBB78CEN

## Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "Nonmuscle invasive bladder cancer - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nonmuscle invasive bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Nonmuscle invasive bladder cancer Understanding

#### Nonmuscle invasive bladder cancer: Overview

Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and

intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.

'Nonmuscle invasive bladder cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nonmuscle invasive bladder cancer pipeline landscape is provided which includes the disease overview and Nonmuscle invasive bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Nonmuscle invasive bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonmuscle invasive bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nonmuscle invasive bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Nonmuscle invasive bladder cancer.

## Nonmuscle invasive bladder cancer Emerging Drugs Chapters

This segment of the Nonmuscle invasive bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Nonmuscle invasive bladder cancer Emerging Drugs

### UGN-102: UroGen Pharma

UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative

technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Nonmuscle invasive bladder cancer.

### Sasanlimab: Pfizer

Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells. PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. Pfizer is developing PF-06801591 for the treatment of Non-muscle Invasive Bladder Cancer and is currently in phase III stage of development.

Further product details are provided in the report.....

### Nonmuscle invasive bladder cancer: Therapeutic Assessment

This segment of the report provides insights about the different Nonmuscle invasive bladder cancer drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Nonmuscle invasive bladder cancer

There are approx. 30+ key companies which are developing the therapies for Nonmuscle invasive bladder cancer. The companies which have their Nonmuscle invasive bladder cancer drug candidates in the most advanced stage, i.e. Phase III include, UroGen Pharma.

#### Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

#### Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Nonmuscle invasive bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Nonmuscle invasive bladder cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nonmuscle invasive bladder cancer therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonmuscle invasive bladder cancer drugs.

### Nonmuscle invasive bladder cancer Report Insights

- Nonmuscle invasive bladder cancer Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Nonmuscle invasive bladder cancer Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

## Unmet Needs

### Key Questions

#### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Nonmuscle invasive bladder cancer drugs?

How many Nonmuscle invasive bladder cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nonmuscle invasive bladder cancer?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nonmuscle invasive bladder cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Nonmuscle invasive bladder cancer and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

UroGen Pharma

CG Oncology

Sasanlimab

Sesen Bio

Theralase Technologies

Asieris Pharmaceuticals

Hamlet Pharma

AstraZeneca

Viralytics

ImmunityBio

Prokarium

Vaxiion Therapeutics

Janssen Pharmaceuticals

Abraxis Bioscience

LIPAC Oncology

Rapamycin Holdings

Incyte Corporation

Taizhou Hanzhong biomedical

## Key Products

UGN-102

CG 0070

Pfizer

Vicineum

TLD-1433

APL-1202

Alpha1H

Durvalumab

CVA 21

Inbakicept

Vesibax

VAX-014

Balversa

ABI-009

TSD-001

eRapa

Pemigatinib

HX008



## Contents

Introduction

Executive Summary

Nonmuscle invasive bladder cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Nonmuscle invasive bladder cancer – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

UGN-102: UroGen Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

TLD 1433: Theralase Technologies

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

VAX-014: Vaxiion Therapeutics

Product Description

Research and Development

Product Development Activities  
Drug profiles in the detailed report.....  
Preclinical/Discovery Stage Products  
    Comparative Analysis  
Vesibax: Prokarium  
    Product Description  
    Research and Development  
    Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
    Comparative Analysis  
Nonmuscle invasive bladder cancer Key Companies  
Nonmuscle invasive bladder cancer Key Products  
Nonmuscle invasive bladder cancer- Unmet Needs  
Nonmuscle invasive bladder cancer- Market Drivers and Barriers  
Nonmuscle invasive bladder cancer- Future Perspectives and Conclusion  
Nonmuscle invasive bladder cancer Analyst Views  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Nonmuscle invasive bladder cancer

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Nonmuscle invasive bladder cancer

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Nonmuscle invasive bladder cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/NAA18BBB78CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NAA18BBB78CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970